125 related articles for article (PubMed ID: 7346837)
41. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial.
Diepeveen SH; Verhoeven GW; Van Der Palen J; Dikkeschei LD; Van Tits LJ; Kolsters G; Offerman JJ; Bilo HJ; Stalenhoef AF
J Intern Med; 2005 May; 257(5):438-45. PubMed ID: 15836660
[TBL] [Abstract][Full Text] [Related]
42. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
[TBL] [Abstract][Full Text] [Related]
43. Effects of L-carnitine supplementation on cardiac morbidity in hemodialyzed patients.
Matsumoto Y; Sato M; Ohashi H; Araki H; Tadokoro M; Osumi Y; Ito H; Morita H; Amano I
Am J Nephrol; 2000; 20(3):201-7. PubMed ID: 10878401
[TBL] [Abstract][Full Text] [Related]
44. [Electromyographic and blood chemical changes in the transition from conservative therapy to short-term hemodialytic treatment. Preliminary data].
Cambi V; Savazzi GM; Arisi L; Allegri L; Bignardi L; Mantovani GP; Rossi E
Minerva Nefrol; 1975; 22(1):22-31. PubMed ID: 174032
[No Abstract] [Full Text] [Related]
45. Short-term effects of nocturnal haemodialysis on carnitine metabolism.
Hothi DK; Geary DF; Fisher L; Chan CT
Nephrol Dial Transplant; 2006 Sep; 21(9):2637-41. PubMed ID: 16822785
[TBL] [Abstract][Full Text] [Related]
46. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
47. [An evaluation of the oral administration of essential amino acids to patients treated by lasting dialysis (author's transl)].
Prejac M; Jeren-Struić B; Straus B; Vitunjski B; Kovarbasić B; Kozjak D
Lijec Vjesn; 1981 Dec; 103(12):555-60. PubMed ID: 7345322
[No Abstract] [Full Text] [Related]
48. Preliminary report on the efficiency of combined haemodialysis-haemoperfusion treatment in chronic uraemia.
Albertazzi A; Cappelli P; Di Paolo B; Evangelista M
Life Support Syst; 1984; 2(4):245-51. PubMed ID: 6527556
[TBL] [Abstract][Full Text] [Related]
49. [Carnitine in patients with renal failure subjected to chronic dialysis therapy].
Wanic-Kossowska M
Pol Tyg Lek; 1992 Dec 7-14; 47(49-50):1118-9. PubMed ID: 1305741
[No Abstract] [Full Text] [Related]
50. The association of lipid levels with mortality in patients on chronic peritoneal dialysis.
Habib AN; Baird BC; Leypoldt JK; Cheung AK; Goldfarb-Rumyantzev AS
Nephrol Dial Transplant; 2006 Oct; 21(10):2881-92. PubMed ID: 16735386
[TBL] [Abstract][Full Text] [Related]
51. Supervised intradialytic oral iron administration during erythropoietin therapy.
Fourtounas C; Koutsikos D; Dalamangas A; Kapetanaki A; Kostoglou M; Agroyannis B; Tzanatos H; Kopelias I; Bosiolis B
Nephrol Dial Transplant; 1996 Jul; 11(7):1485-6. PubMed ID: 8815424
[No Abstract] [Full Text] [Related]
52. L-carnitine supplementation in the dialysis population: are Australian patients missing out?
Reuter SE; Faull RJ; Evans AM
Nephrology (Carlton); 2008 Feb; 13(1):3-16. PubMed ID: 18199095
[TBL] [Abstract][Full Text] [Related]
53. [Determination of serum L-carnitine by an implication of Cobas Bio centrifugal analyzer and its clinical implication in health and disease].
Matsuyama H; Morikawa K; Hasegawa T; Kuroda M
Rinsho Byori; 1988 Nov; 36(11):1296-302. PubMed ID: 3249392
[No Abstract] [Full Text] [Related]
54. [Use of gastrointestinal dialysis in the treatment of chronic renal failure].
Bubiński R; Markiewicz K
Wiad Lek; 1984 Sep; 37(18):1421-5. PubMed ID: 6442494
[No Abstract] [Full Text] [Related]
55. Perturbation of serum carnitine levels in human adults by chronic renal disease and dialysis therapy.
Bartel LL; Hussey JL; Shrago E
Am J Clin Nutr; 1981 Jul; 34(7):1314-20. PubMed ID: 7258121
[TBL] [Abstract][Full Text] [Related]
56. Relationship between serum carnitine, acylcarnitines, and renal function in patients with chronic renal disease.
Fouque D; Holt S; Guebre-Egziabher F; Nakamura K; Vianey-Saban C; Hadj-Aïssa A; Hoppel CL; Kopple JD
J Ren Nutr; 2006 Apr; 16(2):125-31. PubMed ID: 16567268
[TBL] [Abstract][Full Text] [Related]
57. [Effects of L-carnitine on erythropoiesis and blood platelet aggregation in patients with chronic renal failure treated with hemodialysis].
Kalinowski M; Popławski A; Mazerska M; Daniluk A
Pol Merkur Lekarski; 1999 Feb; 6(32):76-8. PubMed ID: 10337176
[TBL] [Abstract][Full Text] [Related]
58. Carnitine action on red blood cell osmotic resistance in hemodialysis patients.
Vlassopoulos DA; Hadjiyannakos DK; Anogiatis AG; Evageliou AE; Santikou AV; Noussias CV; Papandreou PT; Hadjiconstantinou VE
J Nephrol; 2002; 15(1):68-73. PubMed ID: 11936429
[TBL] [Abstract][Full Text] [Related]
59. [When is parenteral carnitine administration indicated?].
Böhles H
Beitr Infusionther Klin Ernahr; 1986; 13():83-99. PubMed ID: 3098227
[No Abstract] [Full Text] [Related]
60. [Clinical and electromyographic study of hemodialysis patients].
Magrotti E; Frascaroli G; Crespi GL; Barbieri C
Riv Neurobiol; 1980; 26(3):327-39. PubMed ID: 6278574
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
